Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02531087 · ClinicalTrials.gov registry record
Urinary Biomarkers of OI Pathobiology
A clinical trial of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
- Active
- Registry status
- 25
- Enrollment target
- 7
- Study locations
NCT02531087: Active study of Osteogenesis Imperfecta, sponsored by Baylor College of Medicine.
NCT02531087 is a study of Osteogenesis Imperfecta that is active but no longer recruiting, run by Baylor College of Medicine. The registered enrollment target is 25 participants, below the 159-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02531087, a study of Osteogenesis Imperfecta, is active but no longer recruiting, sponsored by Baylor College of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 7
- Study locations
Study Summary
Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.
Primary Outcome
The endpoint will be to compare the HP/LP ratio in OI patients with collagen overmodification (dominant negative mutations in COL1A1, COL1A2, and biallelic mutations in CRTAP, LEPRE1, PPIB) to those without overmodification (FKBP10, SERPINH1, IFITM5, SERPINF1, WNT1, and haploinsufficient mutations in COL1A1 and COL1A2).
Conditions Studied
Study Locations (7)
California
- University of California Los Angeles - Los Angeles
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Hospital for Special Surgery - New York
Oregon
- Oregon Health Science University - Portland
Texas
- Baylor College of Medicine - Houston
Wisconsin
- Shriners Hospital for Children - Milwauke
Quebec
- Shriners Hospital for Children - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-08-17 |
| Est. Completion | 2026-08-31 |
What the registry record for NCT02531087 still lists
NCT02531087 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 159-participant average among 13 other Osteogenesis Imperfecta trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Osteogenesis Imperfecta appearing as the primary indexed condition, and to 0 interventions.
NCT02531087 lists 7 locations in 7 states (California, Nebraska, New York).
Frequently Asked Questions
What is clinical trial NCT02531087 about?
NCT02531087 is a clinical study titled "Urinary Biomarkers of OI Pathobiology". Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, ...
What is the current status of trial NCT02531087?
This trial is currently active not recruiting. The enrollment target is 25 participants. The study started on 2015-08-17. Estimated completion is 2026-08-31.
What conditions does trial NCT02531087 study?
This clinical trial studies the following conditions: Osteogenesis Imperfecta.
Who is sponsoring clinical trial NCT02531087?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02531087 being conducted?
This trial has 7 study locations across California, Nebraska, New York, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteogenesis Imperfecta
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02531087's enrollment target sits among peer trials
25 12th of 13 higher than 2 of 13 other Osteogenesis Imperfecta trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteogenesis Imperfecta trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
RECRUITING · Phase 3
-
Effects of Bisphosphonates on OI-Related Hearing Loss
RECRUITING · Phase 4
-
BBD Longitudinal Study of Osteogenesis Imperfecta
RECRUITING
-
Setrusumab vs Placebo for Osteogenesis Imperfecta
ACTIVE NOT RECRUITING · Phase 2
-
Clear Aligners for the Treatment of Dental Malocclusion in OI
ACTIVE NOT RECRUITING · NA
-
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI